Keep it real
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My “axe to grind” is as a shareholder. Our CEO stated multiple times a certain timeline which he then fails to achieve without further explenation. A CEO is as good as his word. A good CEO does not commit to times if he is not in control of the parameters that influence the timeline. He was too ambitious, overpromised and underdelivered.
What happened between the first public mentioning of the AD trial in Nov15 and now? Basically not much. A small extensian trial is ongoing and an outside company did data analytics. Thats about it.
Not too impressive.
Why should we believe Misslilng when he says there will be multiple data read outs ? He also said that multiple trials would start in 2017.
So is BIIB still testing 2-73 for MS??
Yes he is very remarkable, he missed three deadlines after the numerous times he stated and restated them.
Its all blablabla... in October they were still to start 3 trials in Q4 and now they have only submitted an IND for Rett.
Yawn...
Missling chose to state those deadlines and then failed to achieve them. Shareholders seem to pardon any failure of the Good Doctor.
2018 = year of preparatory work
All I hear is delay and delay. Not even Rett can start in 2017. So much for waiting on FDA guidelines.
So no 3 trials starting in 2017.
Not even 1 trial...
Anybody surprised?
Next week will be make or break for the promise of 3 trial starting in 2017.
And confirmed as late as mid-October, in the pk/pd webcast.
So either he was really confident at that time, or something intermediary has happened, or it will happen next week. Next week really is the last week for anything realistic to happen.
I could swear I read the same but then referring to this week.
And yet, no PR's...
I guess speaking is silver and silence is gold.
I remember last time they rang the bell in October15. Result was a turbulent ride up, and down.
Aint gonna go anywhere due safe harbour statement at the start of every presentation.
Correct, he actually addressed this in the previous webcast.
Isn't sad when we are having to have a discussion about the semantics of "starting a trial" ?
You forgot AAIC in July18.
Actually Missling was saying that there could be a possible data readout by end 2017.
Well we know how that went...
Zero news is more correct.
25 days to go.
I fully agree, The Good Doctor would like a fool if he misses his self-imposed, numerously confirmed deadline.
We need accountability. It is not in their best interest when shareholders were to abdicate their responsibility to hold the CEO true to his word.
But I agree, we are not at the end of 2017 yet. But close.
I prefer reality and not let a CEO get away with something so fundamental.
But this is The Good Doctor!?!
All year long he has reiterated three years start before end of year. Now is not the time to go wobbly on promises.
27 days left to salvage his reputation and initiate 3 trials...
Lets get a trial running before dreaming about accelerated approval.
Pending milestones for 2017
initiate Phase 2 clinical trial in Rett
Initiate Phase 2 clinical trial in Parkinson
initiate Phase 2/3 clinical trial in Alzheimer
potential for clinical read-out by end 2017/early 2018
...31 days...
After saying for a whole year that 3 trials will start in 2017, our "Good Doctor" would like a fool if he cannot live up to his promise. And at the very least he owes shareholders an explanation of why the company's actions do not live up to the stated milestones.
31 days
Volume is anaemic, does not support the claim of dilution.
Assuming BIIB would have been interested but after 15 months of testing on MS they went with another compnay
Yeah, we noticed that partnership today. Anavex is like a bride stuck at the alter.
FYI, our CEO is referred to as “The Good Doctor”.
it must be hard to watch when one is holding shares in a company for 13 years.
So when an indication is removed from the presentation that means they are working on it.
Alzheimer etc is still on the presentation. Does that must mean they are not working on it??
But a lot less likely!
Raised enterprise value at this current market cap?
Which partners????
Obviously! 15 months down the road and a partnership for MS with a different company.
But hey let’s not bad mouth the Good Doctor.
Sure BIIB is still testing 2-73 for MS.
Everyone knows and yet nobody partners. Why?